Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARBLI vs ANCEF
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.
First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Spasticity due to multiple sclerosis,Spinal cord injury,Alcohol use disorder (off-label)
Respiratory tract infections,Urinary tract infections,Skin and skin structure infections,Biliary tract infections,Bone and joint infections,Genital infections,Septicemia,Endocarditis,Perioperative prophylaxis
10 mg orally once daily.
1-2 g IV/IM every 8 hours; maximum 6 g/day.
Terminal elimination half-life of 26 hours (range 20-32 h), supporting once-daily dosing; prolonged in hepatic impairment.
1.5-2 hours in adults with normal renal function; prolongs significantly in renal impairment (up to 30 hours in anuria).
Primarily hydrolyzed by esterases to baclofen; baclofen is minimally metabolized (mainly renal clearance of unchanged drug).
Not significantly metabolized; primarily excreted unchanged by renal tubular secretion.
Primarily biliary (>70%) and fecal elimination; renal excretion accounts for <5% of unchanged drug.
Primarily renal (80-90% unchanged by glomerular filtration and tubular secretion); small amounts biliary (<1%) and fecal.
>99% bound to albumin and alpha-1-acid glycoprotein.
80-85% bound to serum albumin.
0.7 L/kg, indicating extensive tissue distribution.
0.14-0.17 L/kg; primarily extracellular fluid.
Oral: 70% (range 60-80%); IV: 100%.
IM: ~100% (well absorbed); IV: 100%.
e GFR ≥30 m L/min/1.73 m²: no adjustment. e GFR <30 m L/min/1.73 m²: use not recommended.
Cr Cl >55 m L/min: 1-2 g every 8 h. Cr Cl 35-54: 1-2 g every 8-12 h. Cr Cl 11-34: 1-2 g every 12 h. Cr Cl <10: 1-2 g every 24-48 h. Hemodialysis: 1-2 g after dialysis.
Child-Pugh A: no adjustment. Child-Pugh B or C: not recommended.
No adjustment required for hepatic impairment.
Not established for patients <18 years.
Infants and children 1 month and older: 25-50 mg/kg/day IV/IM divided every 8 h; severe infections: 100 mg/kg/day divided every 6-8 h. Maximum 6 g/day.
No specific dose adjustment required; monitor renal function.
No specific adjustment; use renal function-based dosing as per renal_adjustment.
Abrupt discontinuation may precipitate withdrawal reactions including seizures, hallucinations, and life-threatening hyperthermia (similar to baclofen withdrawal).
No FDA boxed warnings.
Risk of withdrawal symptoms with abrupt cessation,May cause sedation and dizziness,Use caution in renal impairment,May exacerbate psychiatric disorders,Avoid with alcohol or CNS depressants
Hypersensitivity reactions, including anaphylaxis, especially in patients with penicillin allergy,Clostridium difficile-associated diarrhea,Renal impairment: dose adjustment required,Prolonged use may result in superinfection,Seizures at high doses in renal impairment
Hypersensitivity to baclofen or any component of the formulation
Hypersensitivity to cefazolin or other cephalosporins,History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to penicillins
Avoid alcohol. No specific food interactions reported, but take with or without food consistently to maintain stable drug levels.
No significant food interactions. Cefazolin may be administered with or without food. However, alcohol should be avoided due to potential disulfiram-like reaction (cephalosporin side chain effect).
ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at doses up to 4 times the maximum recommended human dose based on body surface area. However, fetal toxicity (reduced fetal weight, delayed ossification) occurred at maternally toxic doses. Based on mechanism (GABAB agonist), potential risk cannot be excluded. First trimester: unknown risk; second/third trimester: possible risk of fetal harm from maternal muscle relaxation; third trimester: risk of neonatal withdrawal (hypotonia, respiratory depression) if used near term.
No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and third trimesters: no known fetal harm.
No data on excretion in human milk. Arbaclofen is a small molecule (MW 215.68) and likely excreted into breast milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., sedation, respiratory depression) in nursing infants, breastfeeding is not recommended during therapy.
Excreted in breast milk in low concentrations (M/P ratio unknown, likely low). Considered compatible with breastfeeding due to poor oral bioavailability in infants.
No specific dosing guidelines established for pregnancy due to lack of data. Pregnancy may alter pharmacokinetics (increased volume of distribution, renal clearance) potentially requiring dose adjustments; however, no recommendations can be made because drug is contraindicated in pregnancy.
No dosage adjustment recommended for pregnancy. Increased clearance in pregnancy may necessitate higher doses in severe infections, but standard dosing is typically effective.
ARBLI (arbaclofen) is a prodrug of baclofen used for spasticity. Titrate slowly to avoid CNS depression. Monitor renal function; dose adjustment required in Cr Cl <60 m L/min. Avoid abrupt discontinuation due to withdrawal symptoms. Use with caution in patients with history of substance abuse due to abuse potential.
Cefazolin (Ancef) is a first-generation cephalosporin with excellent gram-positive coverage, often used for surgical prophylaxis. It has poor CSF penetration, so it is not suitable for meningitis. Cross-allergenicity with penicillins occurs in approximately 10% of patients. Dose adjustment required in renal impairment (Cr Cl <30 m L/min).
Take exactly as prescribed; do not increase dose without consulting your doctor.,Do not stop taking abruptly; gradual dose reduction is necessary to prevent withdrawal symptoms (hallucinations, seizures, rapid heart rate).,Avoid driving or operating heavy machinery until you know how ARBLI affects you, as it may cause dizziness or drowsiness.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase sedation risk.,Inform your doctor if you have kidney problems, diabetes, or a history of substance abuse.,Store at room temperature away from moisture and heat.
Take exactly as prescribed, even if you feel better.,Complete the full course to prevent resistance.,Report any signs of allergic reaction (rash, itching, difficulty breathing) immediately.,May cause diarrhea; contact your doctor if severe or persistent.,Avoid alcohol during treatment and for 48 hours after last dose (disulfiram-like reaction possible but rare).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARBLI vs ANCEF, answered by our medical review team.
ARBLI is a Cephalosporin Antibiotic that works by ARBLI (arbaclofen placarbil) is a prodrug of baclofen, a GABA-B receptor agonist. It acts presynaptically to inhibit excitatory neurotransmitter release and postsynaptically to reduce neuronal excitability, leading to muscle relaxation.. ANCEF is a Cephalosporin Antibiotic that works by First-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARBLI and ANCEF depend on the specific clinical indication. These are both Cephalosporin Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARBLI is: 10 mg orally once daily.. The standard adult dose of ANCEF is: 1-2 g IV/IM every 8 hours; maximum 6 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARBLI and ANCEF in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARBLI is classified as Category C. ARBLI (arbaclofen) is not approved for use in pregnancy. No adequate and well-controlled studies in pregnant women. In animal studies, arbaclofen showed no teratogenic effects at d. ANCEF is classified as Category C. No evidence of teratogenicity in animal studies. Crosses placenta. Use only if clearly needed during pregnancy. First trimester: limited data, no known malformations. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.